{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:44:59Z","timestamp":1790415899024,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K08 HS026510-01A1"],"award-info":[{"award-number":["K08 HS026510-01A1"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jpeds.2020.05.044","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T21:59:35Z","timestamp":1590616775000},"page":"252-258.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"special_numbering":"C","title":["Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1"],"prefix":"10.1016","volume":"225","author":[{"given":"Amy G.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cullen M.","family":"Dutmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-3956","authenticated-orcid":false,"given":"Aravindhan","family":"Veerapandiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Hafberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara L.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2020.05.044_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jpeds.2020.05.044_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2020.05.044_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2020.05.044_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2020.05.044_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","author":"Kolb","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/0883073807305670","article-title":"Modern management of spinal muscular atrophy","volume":"22","author":"Iannaccone","year":"2007","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib9","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1542\/peds.2004-0668","article-title":"Spinal muscular atrophy: survival pattern and functional status","volume":"114","author":"Chung","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2020.05.044_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","article-title":"Nusinersen for the treatment of spinal muscular atrophy","volume":"17","author":"Chiriboga","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jpeds.2020.05.044_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.05.044_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2005.12.051","article-title":"Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group","volume":"148","author":"Squires","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2020.05.044_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0140-6736(93)91736-6","article-title":"Acute liver failure: redefining the syndromes","volume":"342","author":"O'Grady","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2020.05.044_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jpeds.2020.05.044_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jpeds.2020.05.044_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MPG.0000000000001178","article-title":"Outcomes of children with and without hepatic encephalopathy from the Pediatric Acute Liver Failure Study Group","volume":"63","author":"Ng","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2020.05.044_bib22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hep.20081","article-title":"Hy's law","volume":"39","author":"Reuben","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2020.05.044_bib23","unstructured":"Zimmerman H. Drug-Induced Liver Disease. In: Wilkins LW, editor. Hepatotoxicity, the adverse effects of drugs and other chemicals on the liver, 2nd ed. Philadelphia: Lippincott Williams & Wilkins. p. 428-433."},{"key":"10.1016\/j.jpeds.2020.05.044_bib24","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jpeds.2020.05.044_bib27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.jpeds.2020.05.044_bib28","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpeds.2020.05.044_bib29","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2020.05.044_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jpeds.2020.05.044_bib31","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.05.044_bib32","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.05.044_bib33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/mt.2009.257","article-title":"Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction","volume":"18","author":"Finn","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jpeds.2020.05.044_bib35","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors","volume":"119","author":"Pien","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpeds.2020.05.044_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/hum.2014.106","article-title":"Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial","volume":"26","author":"Monahan","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jpeds.2020.05.044_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jpeds.2020.05.044_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jpeds.2020.05.044_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jpeds.2020.05.044_bib40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/gim.2015.6","article-title":"CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy","volume":"17","author":"Berrier","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2020.05.044_bib41","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.05.044_bib42","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2020.05.044_bib43","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acn3.423","article-title":"New insights into SMA pathogenesis: immune dysfunction and neuroinflammation","volume":"4","author":"Deguise","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib44","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/acn3.50855","article-title":"Abnormal fatty acid metabolism is a core component of spinal muscular atrophy","volume":"6","author":"Deguise","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib45","first-page":"801","article-title":"Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice","volume":"26","author":"Deguise","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpeds.2020.05.044_bib46","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/acn3.50920","article-title":"Low fat diets increase survival of a mouse model of spinal muscular atrophy","volume":"6","author":"Deguise","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jpeds.2020.05.044_bib47","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.05.044_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14712598.2018.1389886","article-title":"Gene therapy for inherited retinal and optic nerve degenerations","volume":"18","author":"Moore","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jpeds.2020.05.044_bib49","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpeds.2020.05.044_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","article-title":"Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial","volume":"1","author":"Chien","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jpeds.2020.05.044_bib51","doi-asserted-by":"crossref","first-page":"165ra3","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jpeds.2020.05.044_bib52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jpeds.2020.05.044_bib53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14712598.2018.1479739","article-title":"The progress of AAV-mediated gene therapy in neuromuscular disorders","volume":"18","author":"Aguti","year":"2018","journal-title":"Expert Opin Biol Ther"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002234762030682X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002234762030682X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:59:01Z","timestamp":1777420741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002234762030682X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":49,"alternative-id":["S002234762030682X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.05.044","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.05.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}